

# ReNeuron Group PLC

08:08 08 May 2019

## ReNeuron well funded for pivotal period clinically and commercially

ReNeuron Group PLC (LON:RENE) revealed it is in a strong financial position as it heads into a pivotal 18 months both clinically and commercially.

Having secured a partnership for its cell technology in China with local company Fosun Pharma, the company confirmed the group is pursuing other collaborations "and/or" out-licensing deals across all its programmes.

ReNeuron in an update reprised the significant clinical headway it has made with successful early studies on patients suffering stroke and those with a blindness causing disease.

### Second group dosed

It also confirmed a second group of three people suffering retinal disease have been dosed with its hRPC cell line. Earlier results revealed the treatment improved eyesight in the first three patients. The vision of this latest trio is more impaired than the first.

In all, ReNeuron expects to dose 12 people suffering from the degenerative condition retinitis pigmentosa with results from the phase IIa study expected by the end of the year.

Dosing for the PISCES III phase IIb clinical trial in 110 stroke patients at up to 40 clinical trial sites in the US began in January with the results expected in the second-half of next year rather than the first-half as planned.

The drug developer said the latest clinical assessment of its CTX therapy, if positive, will be one of two trials required to support marketing authorisations.

### Exomes potential

ReNeuron also said it is "pursuing opportunities to capitalise on the significant scientific and industry interest in its exosomes technology by forming value-generating, business partnerships".

Exosomes are nanoparticles released by cells and contain a number of active proteins and micro RNAs that are believed to play a key role in cell-to-cell communication.

A growing body of evidence demonstrates that exosomes can modulate cellular immunity and promote the activation of regenerative or repair programmes in diseased or injured cells.

The company's CTX cells release large amounts of exosomes when grown in the laboratory enabling its scientists to purify and characterise them.


### First candidate

ExoPr0 is ReNeuron's first CTX-derived exosome therapeutic. It has demonstrated pre-clinical potential as both a

**Price:** 141.5

**Market Cap:** £45.04 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** RENE

**Listing:** LSE

**52 week High Low**  
297.5 71

**Sector:** Pharma & Biotech

**Website:** [www.reneuron.com](http://www.reneuron.com)

#### Company Synopsis:

*ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

treatment and a drug delivery vehicle.

In January the firm told investors it had signed an exomes collaboration agreement with an unnamed US-based group. On Wednesday it revealed it is in "active early discussions" with other commercial third parties.

As at the end of March, the business had just over £29m in the bank. Including the £6m upfront payment from its collaboration with Fosun, ReNeuron reckons it has funds enough for at least the next 12 months.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).